Phase II/III clinical trial of TO-206 - Evaluation of efficacy and safety in patients with Japanese cedar pollinosis

Trial Profile

Phase II/III clinical trial of TO-206 - Evaluation of efficacy and safety in patients with Japanese cedar pollinosis

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 25 May 2016

At a glance

  • Drugs Japanese cedar pollen allergy immunotherapy ALK Abello/Torii Pharmaceutical (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Torii Pharmaceutical
  • Most Recent Events

    • 07 Aug 2015 According to an ALK media release, Tori will proceed with the preparations for submission of an NDA to the Japanese Ministry of Health, Labour and Welfare.
    • 07 Aug 2015 Primary endpoint "Total Combined Rhinitis Score" has been met according to an ALK media release.
    • 09 Feb 2015 According to an ALK-Abello media release, this trial is expected to be completed by 2016 and may form the basis for a registration application.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top